/Hologic%2C%20Inc_%20%20magnified%20-by%20Casimiro%20PT%20via%20Shutterstock.jpg)
Based in Marlborough, Massachusetts, Hologic, Inc. (HOLX) designs and delivers breakthrough medical technologies with a significant emphasis on women’s health. The company has a global presence, offering a range of diagnostic, imaging, and surgical products designed for early detection and effective treatment.
Operating in multiple countries, Hologic is recognized for advancing healthcare with reliable and proven solutions, which help improve patient outcomes and support healthcare professionals worldwide. The company is considered a “large cap” stock, with a market capitalization of $14.75 billion.
Hologic’s stock had reached a 52-week low of $51.90 in May 2025, but it is up 27.8% from this low. Based on a better-than-expected third-quarter earnings report, the stock is up by 3.7% over the past three months. However, the broader S&P 500 Index ($SPX) has outperformed the stock over the same period, gaining 11.4%.
Over the longer term, the stock has declined. Over the past 52 weeks, Hologic’s shares have dropped by 19.5%, while they are down by 8% year-to-date (YTD). On the contrary, the S&P 500 index has gained 16.6% and 13.3% over the same periods, respectively. The stock is currently hovering close to its 50-day and 200-day moving averages.
On July 30, Hologic reported its third-quarter results for fiscal 2025 (the quarter that ended June 28). On the same day, the company’s stock dropped by 1.6%, but rose 2.8% the next day (July 31).
Hologic’s revenue increased 1.2% year-over-year (YOY) to $1.02 billion, which was modestly higher than the $1.01 billion figure that Wall Street analysts were expecting. While the company’s non-GAAP net margin decreased by 100 basis points annually to 23.8%, its adjusted EPS was 1.9% higher than the prior year’s period, at $1.08. The EPS also surpassed the $1.05 figure that Wall Street analysts were expecting.
The company has embarked on a path of seeking growth through strategic acquisitions. Primary among them is the 2021 acquisition of Biotheranostics, which gave Hologic a foot inside the oncology market. This year, Hologic completed the acquisition of Gynesonics, which is expected to strengthen its prospects.
Despite the stock’s underperformance, Wall Street analysts are bullish about Hologic’s prospects. The stock has a consensus rating of “Moderate Buy” from the 20 analysts covering it. The mean price target of $74.38 shows a 12.1% upside compared to current levels. However, the Street-high price target of $94 indicates a 41.7% upside.
